Repurposing Metformin as a Leukemia-preventive Drug in CCUS & LR-MDS

Status Recruiting

Clinical Trial Summary

This is a single-arm pilot study of the feasibility and safety of metformin in patients with clonal cytopenia of undetermined significance (CCUS) or lower-risk myelodysplastic neoplasms (LR-MDS).

Clinical Trial Description

The research plan is divided into three work packages (WP): WP0: Bone Marrow Adipose Tissue, Gut Microbiota, and Intestinal Permeability in CCUS and LR-MDS Patients. The aim of WP0 is to investigate biological features which the investigators hypothesize to be of pathogenetic relevance for MDS progression and may be possible targets of metformin treatment. For this purpose, 20 elderly (≥60 years) healthy controls will be included for comparison to patients with CCUS or LR-MDS from WP1. The primary objectives are to investigate 1) the abundance and properties of bone marrow adipose tissue (BMAT) and bone marrow (BM) adipocytes, and 2) the gut microbiota and intestinal permeability of patients with CCUS or LR-MDS compared to age-, sex- and body mass index (BMI)-matched healthy controls. Secondary objectives are to characterize DNA methylation and hydroxymethylation (5-mC and 5-hmC) patterns, and hormone and cytokine levels in BM plasma from healthy controls and patients with CCUS or LR-MDS. WP1: Safety, feasibility, and mechanisms of action of metformin in patients with CCUS or LR-MDS. In this WP up to 40 patients with CCUS or LR-MDS will receive metformin 2000 mg daily or their maximum tolerated dose (MTD) for 12 months. The aim of WP1 is to investigate safety of metformin and feasibility of the protocol in patients with CCUS or LR-MDS. Potential mechanisms of anti-leukemic action of metformin will also be explored in order to identify a suitable outcome measure and estimate standard deviation of the outcome measure. All in order to inform the design of a future phase 3 RCT of the efficacy of metformin in CCUS and LR-MDS patients. Endpoints of WP1 are specified in the corresponding section. WP2: Safety and efficacy of metformin compared to placebo. The primary objective of WP2 is to compare safety and preliminary efficacy of metformin in patients with CCUS or LR-MDS to a cohort of patients with CCUS or LR-MDS receiving placebo in context of our EVI-2 randomized, controlled pilot study (NCT03999723). Data and samples from approximately 50 historical controls will be included from the EVI-2 study in which participants were randomized to receive placebo or oral vitamin C supplement for 12 months. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04741945
Study type	Interventional
Source	Rigshospitalet, Denmark
Contact	Kirsten Grønbæk, Professor, MD
Phone	+45 35456060
Email	Kirsten.Groenbaek@regionh.dk
Status	Recruiting
Phase	Phase 2
Start date	December 13, 2021
Completion date	June 2026

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02104440` - Clinical Trial In The Treatment Of Allogeneic Post-Transplant Cytopenias With Sequential Infusion Of Allogeneic Mesenchymal Cells Expanded In Vitro	Phase 2
Active, not recruiting	`NCT03682029` - Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid Malignancies	N/A
Recruiting	`NCT03026751` - Improving Diagnosis in Idiopathic Cytopenia Using Gene Sequencing	N/A
Recruiting	`NCT06430788` - A Study of Emapalumab for Pediatric Aplastic Anemia	Phase 2
Recruiting	`NCT04873102` - Danazol for Treatment of Cytopenias in Patients With Cirrhosis	Phase 2
Not yet recruiting	`NCT06285825` - A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia	Early Phase 1
Active, not recruiting	`NCT06276036` - Autoimmune Cytopenias as a Sign of Primary Immunodeficiency.	N/A
Terminated	`NCT03733249` - Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study	Phase 1/Phase 2
Recruiting	`NCT02958462` - Pre-myeloid Cancer and Bone Marrow Failure Clinic Study	N/A
Recruiting	`NCT05236764` - Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion	N/A
Completed	`NCT01928537` - Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine	Phase 3
Recruiting	`NCT04419649` - A Study of KER-050 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes	Phase 2
Completed	`NCT04070612` - National Prospective Cohort for Monitoring Children With Severe Autoimmune Cytopenia.
Active, not recruiting	`NCT03301168` - Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant	Phase 1/Phase 2
Terminated	`NCT02065869` - Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant	Phase 1/Phase 2
Completed	`NCT00367588` - Low Bacterial Diet in Patients With Cytopenia	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Repurposing Metformin as a Leukemia-preventive Drug in CCUS and LR-MDS

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms